2015
Global long-term study on motor and non-motor symptoms and safety of levodopa-carbidopa intestinal gel in routine care of advanced Parkinson's disease patients; 12-month interim outcomes
Abstract: This observational, routine-care study supports long-term safety and efficacy of LCIG infusion in advanced PD including motor, non-motor and QoL improvements.
Search citation statements
Paper Sections
Select...
89
31
19
8
Citation Types
18
148
1
2
Year Published
2015
2026
Publication Types
Select...
120
7
2
2
Relationship
17
114
Authors
Journals
Cited by 128 publications
(169 citation statements)
References 29 publications
18
148
1
2
“…The results confirm and strengthen the findings from earlier studies indicating an antidyskinetic effect of this treatment (12,15,(32)(33)(34)(35)(36). Our results are also in accord with previous studies concerning the effects on off-time and HRQoL in patients with PD.…”
Section: Discussionsupporting
confidence: 93%
“…The results confirm and strengthen the findings from earlier studies indicating an antidyskinetic effect of this treatment (12,15,(32)(33)(34)(35)(36). Our results are also in accord with previous studies concerning the effects on off-time and HRQoL in patients with PD.…”
Section: Discussionsupporting
confidence: 93%
“…Patients treated with LCIG experienced a 57%, 87% and 75% reduction from BL in "Off" time at day 1, M18 and M24, respectively. This reduction in "Off" time was well above what is deemed clinically relevant [29] and was consistent with or even better than published open-label studies and randomised controlled trials on LCIG [8,[16][17][18][19][20][21][22][23][24][25][26] and higher compared to a 65% reduction in "Off" time at M24 demonstrated in the GLORIA registry [26]. In fact, in this sub-population analysis, we found a 77% reduction of the mean daily "Off" time compared to baseline.…”
Section: Discussionsupporting
confidence: 91%
“…This study is the first overview of a cohort of Dutch PD patients treated with LCIG. The results of this study are similar to the findings of previous longterm studies reporting annual rates of withdrawal of 7-13% and an average overall duration of treatment of 7.6 years [10,13,14,16,[30][31][32]. In addition, all baseline characteristics of our cohort, the reported reasons for discontinuation, and the considerably high number of LCIG-related hospitalizations (i.e., serious adverse events) are comparable to the observations in other large patient groups [9,10,13,15,16,20,32].…”
Section: Discussionsupporting
confidence: 90%
